Comprehensive Epigenome-Wide Profiling Reveals Distinctive DNA Methylation Signatures and Potential Prognostic...

Area of Science:

• Epigenetics
• Pediatric Oncology
• Cancer Genomics

Background:

• Acute lymphoblastic leukemia (ALL) is the most frequent childhood cancer.
• Mexico faces higher ALL incidence and lower survival rates, suggesting epigenetic factors like DNA methylation (DNAme) may play a role.
• Understanding the DNA methylation landscape in pediatric ALL is crucial for improving outcomes.

Purpose of the Study:

• To conduct an epigenome-wide association study (EWAS) to define the DNA methylation landscape in pediatric ALL.
• To identify DNA methylation profiles associated with ALL diagnosis and relapse.
• To explore the potential of DNA methylation as prognostic biomarkers for ALL relapse.

Main Methods:

• Analysis of bone marrow or peripheral blood samples from pediatric ALL patients and controls.
• Utilized the Infinium MethylationEPIC v2.0 array for comprehensive DNA methylation profiling.
• Employed the ChAMP package for differential methylation analysis and survival analysis.

Main Results:

• Identified a significant hypermethylated DNA profile in pediatric ALL patients compared to controls.
• MAD1L1 and RPTOR genes showed the most differentially methylated CpG sites.
• Hypomethylation of four specific CpGs (cg01052776 in RNH1, cg20747787, cg05001671, and cg01767116 in FBXL22) was significantly associated with increased relapse risk.

Conclusions:

• Epigenetic mechanisms, particularly DNA methylation, are important in pediatric ALL pathogenesis.
• The identified DNA methylation profiles and specific CpG sites may serve as valuable prognostic biomarkers for ALL relapse.
• Further research into epigenetic modifications could lead to improved therapeutic strategies for pediatric ALL.